Pharmacodynamic Analysis of the HaemOdynamic Effects of a Standard Fluid BolUS

Launched by BICETRE HOSPITAL · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how effective a common treatment for shock is, specifically focusing on the use of a fluid bolus (a quick injection of liquid) to help increase blood flow in patients. When someone is in shock, their heart isn't pumping enough blood, and one way to help is by giving them a large amount of fluid through an IV. However, the researchers want to find out how much of that fluid really helps improve blood flow and how long the benefits last after the treatment stops.

To participate in this study, individuals must be at least 18 years old, be hospitalized in an intensive care unit, and be monitored for their heart function. They also need to be receiving this fluid treatment as decided by their doctors. People who are pregnant or refuse to take part will not be included. If someone joins the trial, they can expect to have their heart's response to the fluid treatment closely monitored to gather important information about its effectiveness. This study aims to improve how shock is treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years old
• • Hospitalisation in intensive care
• • Haemodynamic monitoring already in place with a pulse wave contour analysis-derived estimation of cardiac output (either calibrated or uncalibrated)
• • Decision taken by the clinicians in charge of the patient to perform volume expansion by intravenous infusion of a 6 mL/kg crystalloid bolus
• Exclusion Criteria:
• • Pregnancy
• • Refusal to participate by relatives of the patient or the patient himself
• • Other therapeutic modification during volume expansion